Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RPG Life SciencesNSE:RPGLIFE -0.30%89 3-Year ROIIC % is 16.05 as of Mar. 2026, which is 36% below its 10-year median of 25.05. GuruFocus rates NSE:RPGLIFE with a GF Score™ of 89/100 and a GF Value™ of ₹2,367.80 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 948 Drug Manufacturers companies, RPG Life Sciences ranks better than 67.72% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
RPG Life Sciences's 3-Year ROIIC % for the quarter that ended in Mar. 2026 was 16.05%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for RPG Life Sciences's 3-Year ROIIC % or its related term are showing as below:
NSE:RPGLIFE's 3-Year ROIIC % is ranked better than 67.72% of 948
companies
in the Drug Manufacturers industry
Industry Median: 3.675
vs NSE:RPGLIFE: 16.05
RPG Life Sciences (NSE:RPGLIFE) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
RPG Life Sciences 3-Year ROIIC % Related Terms
RPG Life Sciences 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for RPG Life Sciences's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, RPG Life Sciences's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RPG Life Sciences 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, RPG Life Sciences's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where RPG Life Sciences's 3-Year ROIIC % falls into.
RPG Life Sciences's 3-Year ROIIC % for the quarter that ended in Mar. 2026 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( 946.24761 (Mar. 2026) - 655.75664 (Mar. 2023) )
/
( 3963.8 (Mar. 2026) - 2154.3 (Mar. 2023) )
=
290.49097
/
1809.5
=
16.05%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
RPG Life Sciences (NSE:RPGLIFE) has a 3-Year ROIIC % of 16.05 as of Mar. 2026. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on RPG Life Sciences and its competitors. This is 36% below median its historical median of 25.05. According to the industry distribution chart, RPG Life Sciences ranks #306 out of 948 companies in the Drug Manufacturers industry, placing it in the top 32.3%.
Is RPG Life Sciences' 3-Year ROIIC % too high?
RPG Life Sciences' current 3-Year ROIIC % of 16.05 is 36% below median its 10-year median of 25.05. The Drug Manufacturers industry median 3-Year ROIIC % is 3.68. RPG Life Sciences' value of 16.05 is 336.7% above this industry median. Based on the distribution chart, RPG Life Sciences ranks #306 out of 948 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, RPG Life Sciences has a GF Score™ of 89/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does RPG Life Sciences' 3-Year ROIIC % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, RPG Life Sciences ranks #306 out of 948 companies for 3-Year ROIIC %. This puts RPG Life Sciences in the upper half of its industry. The industry median 3-Year ROIIC % is 3.68. RPG Life Sciences' value of 16.05 is 336.7% above this benchmark. While the company's 10-year median is 25.05 vs. the industry median of 3.68, RPG Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.68, based on 948 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RPG Life Sciences's current 3-Year ROIIC % of 16.05 is 336.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on RPG Life Sciences and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RPG Life Sciences's current 3-Year ROIIC % is 16.05, which is 36% below median its own 10-year median of 25.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RPG Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, RPG Life Sciences (NSE:RPGLIFE) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹2,367.80, compared to a current price of ₹2,928.10 — trading 23.7% above its estimated fair value. The current 3-Year ROIIC % is 16.05, which is 36% below median its 10-year median of 25.05 and 336.7% above the Drug Manufacturers industry median of 3.68. RPG Life Sciences' overall GF Score™ is 89/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For RPG Life Sciences (NSE:RPGLIFE), the current 3-Year ROIIC % is 16.05 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RPG Life Sciences (NSE:RPGLIFE) Overvalued in 2026?
Based on GuruFocus' analysis, RPG Life Sciences stock appears to be overvalued.
The current stock price of ₹2,928.10 is trading 23.7% above its estimated GF Value™ of ₹2,367.80.
GuruFocus considers RPG Life Sciences to be Modestly Overvalued.
Key valuation signals for NSE:RPGLIFE:
3-Year ROIIC %: 16.05 (36% below median its 10-year median of 25.05)
GF Value™: ₹2,367.80 vs. price of ₹2,928.10 (23.7% above fair value)
Industry Position: 336.7% above the Drug Manufacturers median (#306 of 948)
No single metric tells the full story. See the NSE:RPGLIFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RPG Life Sciences Ltd is an integrated pharmaceutical company. Its only reportable segment is the manufacturing and marketing of pharmaceutical products. Geographically, it derives a majority of revenue from India. The company operates across Domestic Formulations, International Formulations and Active Pharmaceutical Ingredients (API). It focuses on Nephrology, Oncology, Urology, Respiratory, Gastrointestinal, Cardiovascular, Gynaecology and Pediatrics, Vitamins and Minerals, Pain Management, Neurology, Anti-Dengue, Anti-Diabetic, and Derma.
89GF Score
Get the complete analysis for NSE:RPGLIFE
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:RPGLIFE has been successfully added to your 
